FDA Committee Recommends Approving First Cell Therapy to Successfully Treat Cancer

Published on in Cancer Connections CHOP News

Emily and family The experimental, personalized cell therapy that amps up the patient's own immune system has passed a critical milestone. An FDA advisory committee was unanimous in recommending full FDA approval of CAR T-cell therapy, which saved the life of Emily Whitehead, the first pediatric patient in the world to receive this treatment. She was cared for here at Children's Hospital of Philadelphia (CHOP). We share the success with the Hospital of the University of Pennsylvania and Novartis Pharmaceuticals. NBC Nightly News with Lester Holt has more on this extraordinary story.

Next Steps
Existing Patients or Family Members
New Patients, Referrals and 2nd Opinions

Referring a Patient

Here’s what you can expect after contacting the Cancer Immunotherapy Program.

Torie CART

Cancer Immunotherapy Studies

The Cancer Immunotherapy Program has several clinical trials available to qualified patients.

You Might Also Like
Emily Whitehead's Story: T Cell Therapy for Acute Lymphoblastic Leukemia

Emily Whitehead's Story: T Cell Therapy for Leukemia

Emily Whitehead was the first child to be enrolled in a clinical trial for patients with B cell cancers such as acute lymphoblastic leukemia.


Cancer Immunotherapy Program

Children with treatment-resistant forms of some cancers may be candidates for treatment with cellular immunotherapy.

CAR T-cell Therapy Process

Here’s what you can expect throughout the CAR T-cell therapy experience.